NEWS. 8:00 AM ET 3/9/17 | PR Newswire. This continues to get teed up.
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Announces Appointment of Dr. Thomas Donnelly to Serve as Senior Veterinary Advisor
Dr. Donnelly is an Internationally Recognized Animal Researcher, who the Company Believes Will Play an Important Role in the Development of Zander's NR2F6 Small Molecule Drug Development Program for Veterinary Applications in Treating Canine Cancer and Arthritis in Animals
Thomas Donnelly, DVM as its Senior Veterinarian Advisor. Dr. Donnelly is an internationally recognized veterinarian researcher and is a certified specialist in the field of laboratory animal medicine, a recognized specialty within the veterinary medical field.
Professor Donnelly's specialty is linking the understanding of animal diseases and their complexities with the development of novel therapies for humans and animals. This ability dovetails in perfectly with Zander Therapeutics' developmental model for veterinary biotechnology. Additionally, he will provide Zander with regulatory guidance, serve as a research adviser and provide direction for the Company's drug development related to animal therapeutics.
"As we move forward in veterinary small molecule drug development, it is extremely important to draw from such an expert as Dr. Donnelly in charting the course our research takes. His tremendous expertise and international reputation will help us facilitate our goal - to develop novel therapeutics to help dogs, cats and horses recover from common diseases that they are susceptible to such as arthritis and cancer," said David Koos, Ph.D., Chairman and CEO of Zander.
News 
Market Data 
Discover 
